Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaq
Tweet Content
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/Eo4LMaTHxn https://t.co/abzlThasEN
Links
BIMZELX[®] Approved by the U.S. FDA for the Treatment of Adults with Moderate t…
https://bit.ly/3S9ekI5
Show on Archive Page
On
Display in Search Results
On
PDQ
Off